Clinical Trials News - Candlesense

Research Shows Medtechs Prioritizing Site Collaboration and Data Quality

Nearly 70% say reducing manual processes is a key priority for working with sites PLEASANTON, Calif., Aug. 12, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced findings from the 2025...

How might the sentiment score of 55 and the overall market sentiment impact investor perception and trading volume for VEEV? Could this shift in medtech priorities accelerate Veeva's product development roadmap or pricing strategy, and what effect would that have on margins? What are the potential short‑term price reactions versus the long‑term valuation implications of this news for VEEV?

Symbol: VEEV

11 days ago

AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry ...

Could any unexpected pharmacokinetic findings alter the dosing strategy or development timeline for AN2‑502998? What is the anticipated impact on ANTX's cash burn and financing needs if the program progresses to later‑stage trials? How does the size and composition of the healthy volunteer cohort compare to industry standards for first‑in‑human studies?

Symbol: ANTX

11 days ago

Read more businesswire

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizop...

How does the sentiment score of 35 influence market expectations for this announcement? What are the regulatory implications if the trial demonstrates positive results for an FDA or EMA submission? How might this news affect the trading volume and liquidity of Newron’s stock (NWRN)?

Symbol: NWRN

11 days ago

Read more businesswire

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal s...

What risks remain that could offset the positive data, such as safety signals in larger populations or competitive trial results? How could the Phase 2b results influence partnership or licensing discussions with larger pharma companies? What is the expected impact on VERU’s cash burn and financing needs given the need to fund Phase 3 development?

Symbol: VERU

11 days ago

Read more globenewswire

KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-30...

Is there any indication that Merck will expand the combination into earlier‑line or adjuvant settings based on these results? How will the combination’s efficacy metrics (event‑free survival, overall survival, pCR) influence payer reimbursement strategies? What are the key inclusion/exclusion criteria of the KEYNOTE‑905 trial that could affect the broader patient population eligibility?

Symbol: MRK

12 days ago

Read more businesswire

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive topline results from the Phase...

Are there any upcoming conference presentations or analyst calls where more details will be disclosed? Will the positive results affect the valuation of Astellas (4503) and its partnership with Pfizer? What impact could this have on the broader oncology pipeline and investor sentiment toward Pfizer’s oncology segment?

Symbol: PFE

12 days ago

Read more businesswire

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

How will the trial results impact the valuation of Novartis' pipeline and overall corporate pipeline risk profile? Could this success lead to further investment or partnership opportunities for Novartis in the ITP space? What is the anticipated market size for ianalumab in ITP and how could it affect Novartis' market share?

Symbol: NVS

12 days ago

Read more globenewswire

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focus...

How might the conference presentation affect analyst estimates and price targets? What is the current share ownership structure and any recent insider transactions? What are the competitive dynamics in the MASH therapeutic space and who are the key competitors?

Symbol: IVA

12 days ago

Read more globenewswire

Sonnet Releases Virtual Investor "What This Means" Segment

- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)

How does the expansion align with Sonnet's overall pipeline and strategic priorities? What is the anticipated impact on Sonnet's stock price in the short term? How might the trial expansion impact Sonnet's share dilution or financing needs?

Symbol: SONN

12 days ago

Read more globenewswire

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wit...

What is the anticipated impact on the company’s overall valuation if the Phase 2a data support progression to later‑stage trials? How might the trial results, whether positive or negative, influence analyst coverage, consensus estimates, and forward‑looking guidance for TLSA? Are there any partnership or licensing agreements in place or being pursued that could accelerate development or de‑risk the program?

Symbol: TLSA

12 days ago

Read more globenewswire